Aureka Biotechnologies, Inc.


Aureka Biotechnologies is a biotech startup dedicated to democratizing the pharmaceutical industry through integrated digital biology and AI solutions. Their mission is to improve human health by digitalizing and democratizing therapeutic discovery, aiming to significantly reduce costs and time, and enable novel treatments for challenging targets. They focus on high-throughput synthetic biology, single-cell functional screening, AI-based drug design, and autonomous evolution to accelerate therapeutic discovery. Their vision is to design high-value protein therapeutics at scale using a transformative, data-driven AI platform.

Industries

biotechnology
pharmaceutical

Nr. of Employees

small (1-50)

Aureka Biotechnologies, Inc.

23181 Verdugo Drive, Suite 106, Laguna Hills, CA 92653


Products

Rapid generation of potent antibodies by autonomous hypermutation in yeast (publication)

Scientific publication describing autonomous hypermutation in yeast as a method for rapid antibody generation and evolution.

A high throughput bispecific antibody discovery pipeline (publication)

Scientific publication describing a high-throughput pipeline for bispecific antibody discovery, including microfluidic methods.


Services

Collaborative co-discovery engagements that provide partners access to an integrated digital-biology and AI platform to design and optimize protein therapeutics and difficult antibody targets.

Expertise Areas

  • Digital biology and AI-driven therapeutic design
  • High-throughput screening and single-cell assays
  • Synthetic biology and directed evolution
  • Antibody and protein therapeutic engineering
  • Show More (3)

Key Technologies

  • Single-cell functional screening
  • High-throughput synthetic biology and library construction
  • Autonomous directed evolution in yeast
  • Microfluidics for antibody discovery
  • Show More (4)

News & Updates

Participation in the 2025 event focused on antibody therapeutics.

Participation in the 2025 symposium series on speeding drug discovery with AI/ML.

Participation in the 2025 conference for life science partnering and investment.

Participation in the 2025 SLAS conference and exhibition.

Participation in the 2024 event focused on antibody therapeutics.

Participation in the 2024 BioLogic Summit.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.